Shares in Galapagos NV were down 9 percent Friday on news that Glaxosmithkline plc terminated development of its selective Janus kinase 1 (JAK1) inhibitor GSK2586184 in several chronic inflammatory conditions after a statin-associated drug-drug interaction became apparent in a phase I study.